India's Piramal investing $55M in API production

Piramal Pharma Solutions, which bought Michigan-based Ash Stevens last year, says it is investing $55 million across its manufacturing network to improve and expand its API manufacturing capabilities.

Indian CDMO Piramal Pharma Solutions is beefing up its global API production, including in the U.S., where it has expanded in recent years.

The company said on Tuesday that it would invest $55 million across its network. In addition to upgrades in manufacturing automation and IT across its entire network, specific projects include expanding its early development capabilities at a site in Morpeth, U.K., and its high-potency drug capabilities at its site in Riverview, Michigan.

RELATED: India's Piramal buys another U.S. manufacturer

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Piramal picked up the Michigan operation last year when it agreed to pay up to $53 million in cash and milestone payments for Riverview-based Ash Stevens. With that deal, it acquired 60,000 square feet of facilities, eight chemical drug development and production laboratories, and six full-scale production areas, including facilities for high-potency API manufacturing.

RELATED: India's Piramal to buy U.S. maker of sterile injectables, antibody drug conjugates

In January 2015, Piramal agreed to pay $30.65 million to buy Coldstream Laboratories from the University of Kentucky to get its expertise in sterile injectable medications.

Indian companies have been aggressive buyers of small- to medium-sized U.S. operations in the last few years. Mumbai-based Lupin Pharmaceuticals bought two New Jersey generics companies last year for a total of almost $900 million. In 2015, Cipla paid $550 million for InvaGen Pharmaceuticals, a Hauppauge, New York-based generics maker, and its marketing operation, picking up a 350,000-square-foot manufacturing plant in the deal.

Read more on

Suggested Articles

Indian drugmakers pick up U.S. generics scripts; Chi-Med files for Hong Kong listing; an explosion at a Qilu Pharma subsidiary kills 10.

Traditional generics bigwigs Teva, Mylan, Sandoz, Amneal and Endo have lost out to a group of six competitors in terms of U.S. weekly prescriptions.

As a key global ingredient supplier, problems in China can ripple worldwide as they have for Swiss CDMO Lonza.